Changes in serum lipid profile during and after pegylated IFN and ribavirin therapy in chronic hepatitis C
Abstract number: R2482
Zangi M., Akbarian E., Alavian S., Ghojavand A., Safavi naeini P., Yavari M.
Objectives: chronic Hepatitis C is one of the most significant health problems worldwide. At present, the most effective therapy available for the treatment of HCV infection is the combination of pegylated IFN (pegIFN) and ribavirin and using such therapy is associated with a wide range of systemic side effects and complications such as metabolic changes. In fact, its use has been associated with a change in serum triglyceride and cholesterol levels.
Therefore, we designed this study to investigate changes in serum lipid concentrations during and after therapy with pegylated interferon in combination with ribavirin in these patients.
Methods: 71 patients with active chronic hepatitis C were enrolled in this study and received Pegylated interferon at a dose of 180 mg in combination with ribavirin at a dose of 10001200 mg, daily for 48 weeks. Blood samples were collected before, during (3 months after the start of), at the completion of and after (6 months after the completion of) IFN therapy.
Results: 65 male (91.5%) and 6 female (8.5%) with the mean age of 37.9 years were evaluated. mean serum triglyceride levels rose from 105 mg/dL to 129 mg/dL at the third month and 134 mg/dL at the completion of therapy (p < 0.0001). Afterward, mean serum triglyceride levels decreased to 130 mg/dL six months after stopping therapy.
Serum cholesterol levels had no significant changes during the same time period; however, decreased levels during the therapy were noted and returning levels to baseline were seen 6 months after stopping therapy. Thus, levels decreased from 154 mg/dL to 147 mg/dL at the third month and 145 mg/dL at the completion of therapy; subsequently, levels returned to baseline by 6 months after stopping therapy (mean 156 mg/dL).
Conclusion: We clarified that Serum triglyceride levels increases consistently in patients with chronic hepatitis C during therapy and returns to normal after it, while serum cholesterol level follows the opposite trend.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|